Several studies have reported that ERCC1 expression can be an independent prognostic factor of cancer patients receiving chemotherapy.14-17 Li et al. reported that drug resistance to cisplatin in gastric carcinoma is correlated with increased expression of ERCC1.15 Muallem et al. reported that the low levels of ERCC1 expression was not associated with unfavorable outcomes of patients with locally advanced cervical cancer and ovarian cancer.14,16. The gene discussed is ERCC1; the disease is ovarian cancer.